SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
SRPT reported Q3 2026 results. The stock moved +1.4% on the print.
SRPTearnings

Earnings reactions, page 5

Sarepta Therapeutics, Inc. (SRPT) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenues were $381.4 million for the third quarter of 2026 compared to $399.4 million for the third quarter of 2025.
  • Net product revenues for the third quarter of 2026 totaled approximately $323.8 million, consisting of approximately $240.3 million of PMO net product revenues and $83.5 million of ELEVIDYS net product revenue.
  • GAAP operating loss was ($9.0) million for the third quarter of 2026 compared to ($103.4) million for the third quarter of 2025.
  • Non-GAAP operating income was $22.9 million for the third quarter of 2026 compared to non-GAAP operating loss of ($35.7) million for the third quarter of 2025.
  • GAAP diluted loss per share was ($0.27) for the third quarter of 2026 compared to ($0.50) for the third quarter of 2025.
  • Non-GAAP diluted earnings per share was $0.13 for the third quarter of 2026 compared to non-GAAP diluted loss per share of ($0.13) for the third quarter of 2025.

Guidance

  • Company expects ELEVIDYS net product revenue in the fourth quarter to trend in line with the third quarter.
  • Company is updating its full-year guidance ranges, raising the low end of total net product revenue guidance by $50.0 million to a range of $1.25 billion to $1.3 billion.
  • Company narrows its full-year combined non-GAAP R&D and SG&A expenses, lowering the high end of expense guidance by $25.0 million to a range of $800 million to $825 million.

Notes

GAAP net loss and diluted loss per share for the three and nine months ended September 30, 2025 have been revised to reflect the correction of an immaterial error associated with the accounting for the August 2025 Exchange, as well as the adoption of ASU 2025-07.

Price and volatility reaction

The stock moved +1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -41.6 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release17.572026-11-05
Close after release17.822026-11-06
Realised move+1.4%close to close
30d ATM IV change-41.6 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →